Intravenous Immunoglobulin Market

Market Overview:

The 7 major intravenous immunoglobulin markets reached a value of US$ 12.7 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 23.5 Billion by 2034, exhibiting a growth rate (CAGR) of 5.76% during 2024-2034.

The intravenous immunoglobulin market has been comprehensively analyzed in IMARC's new report titled "Intravenous Immunoglobulin Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Intravenous immunoglobulin (IVIG) refers to a pooled antibody and biological agent derived from human blood plasma. It is used to treat a wide range of medical conditions that affect the immune system and cause a deficiency of antibodies. The composition of IVIG products is similar to that of immunoglobulins found in normal human plasma, including IgG, IgA, traces of other Igs, soluble receptors, cytokines, etc. Based on the formulation, it is generally administered by injecting into a muscle, vein, or under the skin. IVIG can be utilized in various treatment protocols, including replacement therapy for patients with primary and secondary immunodeficiencies. It may also be used to aid in the prevention of infections in individuals who have undergone an organ or stem cell transplant. This therapy offers numerous advantages, such as low toxicity, targeted delivery, long-term effectiveness, quicker onset of action, etc. The dosage and frequency of IVIG treatment depend on the specific condition being treated and the patient's individual needs.

The rising incidence of immunodeficiency disorders, such as acquired immunodeficiency syndrome (AIDS) and primary immunodeficiency diseases (PIDs), is primarily driving the intravenous immunoglobulin market. In addition to this, the expanding geriatric population, who are more susceptible to infections and other immune-related ailments, is further creating a positive outlook for the market. Moreover, the emerging popularity of subcutaneous administration of IVIG on account of its several benefits over intravenous administration, such as a lower risk of infection, reduced incidence of infusion-related reactions, convenience, etc., is acting as another significant growth-inducing factor. Besides this, the escalating utilization of off-label IVIG for numerous indications, including inflammatory bowel disease, dermatological conditions, neurological disorders, etc., since it modulates the immune system and provides the body with antibodies, is also bolstering the market growth. Furthermore, the ongoing advancements in formulation and stabilization techniques that have increased the efficiency and scale of production, thereby lowering the cost of the therapy, are expected to drive the intravenous immunoglobulin market in the coming years.

IMARC Group's new report provides an exhaustive analysis of the intravenous immunoglobulin market in the United States, EU4 (Germany, Spain, Italy, and France), United Kingdom, and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report, the United States has the largest patient pool for intravenous immunoglobulin and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario, unmet medical needs, etc., have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the intravenous immunoglobulin market in any manner.

Recent Developments:

• In June 2024, Grifols reported that Biotest, a Grifols Group company, had received approval from the FDA for Yimmugo, an emerging intravenous immunoglobulin (Ig) therapy used to treat primary immunodeficiencies
• In July 2023, GC Biopharma reported that the FDA had accepted the company's resubmission of the biologics license application for its GC5107B (Immune Globulin Intravenous (Human) for individuals suffering from primary humoral immunodeficiency.

Key Highlights:

• Intravenous immunoglobulin is a concentration of immunoglobulins obtained from 1000 to 100,000 healthy donors, depending on the manufacturer.
• IVIG is more commonly used for streptococcal toxic shock and necrotizing fasciitis.
• IgG accounts for over 90% of the proteins in an IVIG preparation and is the primary component necessary for the therapeutic efficacy of IVIG.
• IVIG doses of 400 to 800 mg/kg/month are used to treat immunological deficiencies.

Drugs:

ASCENIV (immune globulin intravenous, human - slra) is a 10% immune globulin liquid for intravenous injection used to treat primary humoral immunodeficiency (PI) in adults and adolescents (12 to 17 years old). It is the only IVIG created by combining RSV plasma with normal source plasma.

GC5107 refers to a liquid solution containing 10% immunoglobulin G (100 mg/mL) for intravenous infusion, derived from pooled human plasma from US donors. The manufacturing method consists of three phases designed to decrease the possibility of virus transmission. The steps are the following: fractionation I and III, solvent/detergent (S/D) treatment, and nanofiltration.

BT-595 is under development by Biotest for the treatment of primary immune deficiency, idiopathic thrombocytopenic purpura and scleromyxedema (dermatology). The solution is injected intravenously. The drug candidate is a polyvalent human IgG.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034
   

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the intravenous immunoglobulin market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the intravenous immunoglobulin market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current intravenous immunoglobulin marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the intravenous immunoglobulin market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the intravenous immunoglobulin market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the intravenous immunoglobulin market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin across the seven major markets?
• What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of intravenous immunoglobulin by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with intravenous immunoglobulin across the seven major markets?
• What is the size of the intravenous immunoglobulin patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of intravenous immunoglobulin?
• What will be the growth rate of patients across the seven major markets?
   

Intravenous Immunoglobulin: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for intravenous immunoglobulin drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the intravenous immunoglobulin market?
• What are the key regulatory events related to the intravenous immunoglobulin market?
• What is the structure of clinical trial landscape by status related to the intravenous immunoglobulin market?
• What is the structure of clinical trial landscape by phase related to the intravenous immunoglobulin market?
• What is the structure of clinical trial landscape by route of administration related to the intravenous immunoglobulin market?